Literature DB >> 29365117

Progression of tremor in early stages of Parkinson's disease: a clinical and neuroimaging study.

Jacopo Pasquini1, Roberto Ceravolo1, Zahi Qamhawi2, Jee-Young Lee2,3, Günther Deuschl4, David James Brooks5,6, Ubaldo Bonuccelli1, Nicola Pavese5,6.   

Abstract

Rest tremor is one of the cardinal signs of Parkinson's disease. Kinetic and postural tremors may also occur. The coexistence of these three types of tremor at disease onset and their subsequent progression could have important clinical and therapeutic implications but remain to be fully elucidated. We aimed to: (i) evaluate prevalence and progression of these three types of tremor in early stages of the disease; and (ii) investigate longitudinally the relationship between dopaminergic and serotonergic terminal dysfunction, rest tremor severity and its response to dopaminergic therapy. The Parkinson's Progressive Markers Initiative database provided the baseline and 2-year follow-up clinical ratings and 123ioflupane-fluoropropyl-carbomethoxy-3-beta-4-iodophenyltropane (123I-FP-CIT) single photon emission computed tomography images for this study. 123I-FP-CIT measured putamen dopamine transporter and median raphe serotonin transporter availability. A raphe/putamen uptake ratio was calculated for each patient as an index of relative involvement of these structures. Clinical analysis of tremor was conducted on 378 patients: 87.8% presented with tremor at baseline; rest tremor occurred in 69.6% of patients at baseline; and 67.9% at follow-up. Postural and kinetic tremors occurred in about 50% of patients at both baseline and follow-up. Over 20% of patients presenting with tremor did not exhibit a rest component at baseline. The number of patients with isolated rest tremor was halved at follow-up. In tremor predominant patients, rest tremor severity was inversely correlated with raphe serotonin transporter availability both at baseline and follow-up (baseline: constancy P < 0.05, tremor index P < 0.05; follow-up: amplitude P < 0.05, constancy P < 0.05, tremor index P < 0.05). In the entire cohort, more severe tremor scores correlated with lower raphe/putamen uptake ratio values, indicative of more severe raphe dysfunction (baseline: constancy P < 0.01, tremor index P < 0.05; follow-up: amplitude P < 0.01, constancy P < 0.001, tremor index P < 0.001). The percentage of improvement in rest tremor amplitude after acute dopaminergic therapy was smaller in patients with lower raphe/putamen uptake ratio values (P < 0.01). Rest tremor is the most represented type of tremor in early Parkinson's disease. However, postural and kinetic tremor can affect approximately half of these patients and can occur in absence of resting tremor. As disease progresses, both raphe serotonergic dysfunction and putamen dopamine depletion could contribute to the occurrence of rest tremor. The former is linked to more severe tremor scores and poorer response to dopaminergic therapy. Non-dopaminergic treatments might be beneficial for patients whose tremor is associated with a raphe-predominant dysfunction.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29365117     DOI: 10.1093/brain/awx376

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  21 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

2.  Development and Assessment of a Movement Disorder Simulator Based on Inertial Data.

Authors:  Chiara Carissimo; Gianni Cerro; Luigi Ferrigno; Giacomo Golluccio; Alessandro Marino
Journal:  Sensors (Basel)       Date:  2022-08-23       Impact factor: 3.847

Review 3.  A review on pathology, mechanism, and therapy for cerebellum and tremor in Parkinson's disease.

Authors:  Yuke Zhong; Hang Liu; Guohui Liu; Lili Zhao; Chengcheng Dai; Yi Liang; Juncong Du; Xuan Zhou; Lijuan Mo; Changhong Tan; Xinjie Tan; Fen Deng; Xi Liu; Lifen Chen
Journal:  NPJ Parkinsons Dis       Date:  2022-06-24

Review 4.  Imaging Markers of Progression in Parkinson's Disease.

Authors:  Antonio P Strafella; Nico I Bohnen; Nicola Pavese; David E Vaillancourt; Thilo van Eimeren; Marios Politis; Alessandro Tessitore; Christine Ghadery; Simon Lewis
Journal:  Mov Disord Clin Pract       Date:  2018-10-09

5.  Atypical Parkinsonian Syndromes and Subtypes of Parkinson's Disease. Will a Single Neuroimaging Modality Ever Be Enough?

Authors:  Nicola Pavese
Journal:  Mov Disord Clin Pract       Date:  2021-01-08

6.  Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Prabesh Kanel; Robert A Koeppe; Carlos A Sanchez-Catasus; Kirk A Frey; Peter Scott; Gregory M Constantine; Roger L Albin; Martijn L T M Müller
Journal:  Brain Commun       Date:  2021-05-22

7.  Brainstem Raphe Alterations in TCS: A Biomarker for Depression and Apathy in Parkinson's Disease Patients.

Authors:  Daniel Richter; Dirk Woitalla; Siegfried Muhlack; Ralf Gold; Lars Tönges; Christos Krogias
Journal:  Front Neurol       Date:  2018-08-07       Impact factor: 4.003

Review 8.  Gut Microbial Metabolites in Parkinson's Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment.

Authors:  Yixuan Liang; Li Cui; Jiguo Gao; Mingqin Zhu; Ying Zhang; Hong-Liang Zhang
Journal:  Mol Neurobiol       Date:  2021-04-06       Impact factor: 5.590

9.  Association Between Peripheral Inflammation and DATSCAN Data of the Striatal Nuclei in Different Motor Subtypes of Parkinson Disease.

Authors:  Hossein Sanjari Moghaddam; Farzaneh Ghazi Sherbaf; Mahtab Mojtahed Zadeh; Amir Ashraf-Ganjouei; Mohammad Hadi Aarabi
Journal:  Front Neurol       Date:  2018-04-16       Impact factor: 4.003

10.  Re-Emergent Kinetic Tremor in Parkinson's Disease.

Authors:  Harsh V Gupta
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.